Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | Chief Legal Officer | September 01, 2026 | September 03, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Chief Adm, Leg & BD Off | February 24, 2021 | February 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-09-01 | Direct | 7,405 |
Reported balance
After 2026-09-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 7,405 · Balance 7,405 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of September 1, 2026.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,837 |
Ending reported balance
After 2021-02-25 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2021-02-24 · Tax withholding · Disposed 2,416 · Balance 33,865 Row 2 · 2021-02-25 · Sale · Disposed 646 · Balance 33,219 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91). F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Row 3 · 2021-02-25 · Sale · Disposed 1,348 · Balance 31,871 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68). Row 4 · 2021-02-25 · Sale · Disposed 680 · Balance 31,191 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69). Row 5 · 2021-02-25 · Sale · Disposed 354 · Balance 30,837 F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76). |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $211.58 (range $211.34 to $211.91).
F3: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $213.04 (range $212.76 to $213.68).
F5: Open market sales reported on this line occurred at a weighted average price of $214.28 (range $213.90 to $214.69).
F6: Open market sales reported on this line occurred at a weighted average price of $216.26 (range $215.79 to $216.76).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 26, 2018 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 38,250 | $122.45 | $4,683,712.50 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · nonDerivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · derivative · entry 6 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,125 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/12/2016. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 300 | $156.36 | $46,908.00 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,609 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $156.36 (range $155.97 to $156.75). Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,214 | $155.07 | $343,324.98 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,909 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $155.07 (range $154.61 to $155.56). F3 · price: Mr. Parini undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2018 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2018 Filed Feb 14, 2018 22:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 12,136 | $153.41 | $1,861,783.76 |
DisclosureSEC source: 0001209191-18-010038 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,998 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 19,566 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008539 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,566 Underlying: Common Stock · 19,566 shares Expires 2028-02-05 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 8,437 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008539 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,134 F2 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:17 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008539 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,697 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2017 that contained both performance-vesting and service-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2018. The earned performance shares remain subject to the service-vesting requirements and will vest in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-18-008198 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,959 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,330 | $163.08 | $379,976.40 |
DisclosureSEC source: 0001209191-18-008198 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,493 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 05, 2018 Filed Feb 7, 2018 22:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-18-008198 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2018 Filed Feb 5, 2018 22:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,450 | $174.11 | $600,679.50 |
DisclosureSEC source: 0001209191-18-007604 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,493 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-18-003628 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/12/2016. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,125 | $157.16 | $333,965.00 |
DisclosureSEC source: 0001209191-18-003628 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,943 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| January 12, 2018 Filed Jan 16, 2018 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-18-003628 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-059637 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,289 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,330 | $149.50 | $348,335.00 |
DisclosureSEC source: 0001209191-17-059637 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,809 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| November 03, 2017 Filed Nov 7, 2017 22:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-17-059637 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,125 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-17-057018 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,375 Underlying: Common Stock · 2,125 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 7/12/2016. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,125 | $152.93 | $324,976.25 |
DisclosureSEC source: 0001209191-17-057018 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,809 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 20:59 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,125 | $90.29 | $191,866.25 |
DisclosureSEC source: 0001209191-17-057018 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-047723 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,619 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/3/2017. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,330 | $155.72 | $362,827.60 |
DisclosureSEC source: 0001209191-17-047723 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,809 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| August 03, 2017 Filed Aug 4, 2017 20:45 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-17-047723 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,329 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-046028 · doc4.xml · derivative · entry 5 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,949 Underlying: Common Stock · 2,329 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-17-046028 · doc4.xml · derivative · entry 4 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,500 Underlying: Common Stock · 8,500 shares Expires 2026-07-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 10,829 | $161.00 | $1,743,469.00 |
DisclosureSEC source: 0001209191-17-046028 · doc4.xml · nonDerivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,809 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 2,329 | $86.52 | $201,505.08 |
DisclosureSEC source: 0001209191-17-046028 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 19, 2017 Filed Jul 22, 2017 00:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionCommon Stock | 8,500 | $90.29 | $767,465.00 |
DisclosureSEC source: 0001209191-17-046028 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,309 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 37,278 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-17-008399 · doc4.xml · derivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,278 Underlying: Common Stock · 37,278 shares Expires 2027-02-02 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 21:57 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 18,204 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-008399 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,554 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/10/2018, 2/10/2019 and 2/10/2020. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,450 | $85.98 | $296,631.00 |
DisclosureSEC source: 0001209191-17-007630 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CLO & CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,350 F1 · kind: Transaction made pursuant to Mr. Parini's company approved trading plan under Rule 10b5-1. Read SEC document |
| July 12, 2016 Filed Jul 14, 2016 20:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $90.29 | $0.00 |
DisclosureSEC source: 0001209191-16-132723 · doc4.xml · derivative · entry 1 Parini Michael · CIK 0001661567 · EVP & CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2026-07-11 F1 · derivative.exercise_date: The option vests in 16 quarterly installments from 07/12/2016. Read SEC document |
| April 26, 2016 Filed Apr 27, 2018 20:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,250 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-18-026609 · doc4.xml · derivative · entry 7 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,750 Underlying: Common Stock · 38,250 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 1/4/2016. Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (right to buy) · Derivative | 68,000 | $0.00 Strike: $122.45 | $0.00 |
DisclosureSEC source: 0001209191-16-089945 · doc4.xml · derivative · entry 2 Parini Michael · CIK 0001661567 · EVP & CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2026-01-03 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 01/04/2016. Read SEC document |
| January 04, 2016 Filed Jan 6, 2016 22:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 13,800 | $0.01 | $138.00 |
DisclosureSEC source: 0001209191-16-089945 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP & CLO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 F1 · shares: Stock grant under 2013 Stock and Option Plan, vesting in four annual installments from 01/04/2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.